Recently published guideline highlights TAVR for treatment of valvular heart disease1

The ACC/AHA released key updates in their recent 2020 guideline for Valvular Heart Disease, including new guidance for the treatment of severe symptomatic aortic stenosis and transcatheter valve repair/implantation.

In its ‘Top 10 Take-Home Messages’, the ACC/AHA now recommends that

"All patients with severe valvular heart disease being considered for valve intervention should be evaluated by a multidisciplinary team..."1

When intervention is considered, patients should be evaluated by a Heart Team (Class 1C-EO)

Engagement between the Heart Team and the primary clinical cardiologist is of critical importance

Recommendations for intervention now focus on age and shared decision-making

For SAS patients 65 to 80 years old, TAVR/I should be considered, based on shared decision-making

TAVR/I is an effective approach to aortic valve replacement in adults 65 to 80 years of age.

2020 ACC/AHA Guideline on intervention recommendations by age1

Indications for TAVR are expanding as a result of multiple randomized trials, including the latest PARTNER Trials, which are reflected in these recommendations.

Recommendations shift their focus

Consider even more patients for a TAVR evaluation with the support and confidence of the latest ACC/AHA Guideline.

Recommended resources

See all resources

Be the first to know about the latest updates in the treatment of valvular heart disease, and find out about new events.

Stay Informed

References:   1. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020. Epublished DOI: 10.1016/j.jacc.2020.11.018.